Tarlox-TKI

CAS No. 2135696-72-7

Tarlox-TKI( —— )

Catalog No. M32984 CAS No. 2135696-72-7

Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, with antitumor activity.Tarlox-TKI inhibits NRG1 and suppresses HER2 mutants.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 255 In Stock
2MG 225 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Tarlox-TKI
  • Note
    Research use only, not for human use.
  • Brief Description
    Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, with antitumor activity.Tarlox-TKI inhibits NRG1 and suppresses HER2 mutants.
  • Description
    Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbB TKI (Tarlox-TKI).
  • In Vitro
    Epidermal Growth Factor Receptor (EGFR, HER1) is an attractive therapeutic target for many cancer types. Tarlox-TKI is a dose-potent EGFR inhibitor.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2135696-72-7
  • Formula Weight
    461.74
  • Molecular Formula
    C19H18BrClN6O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (216.57 mM; Ultrasonic )
  • SMILES
    CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Victoria Jackson-Patel, et al. Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies.
molnova catalog
related products
  • Nimotuzumab

    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).

  • EAI001

    EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.EAI001 can be used in cancer research.

  • Erlotinib

    A potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.